Investor Presentation: First Nine Months of 2020
5
Investor presentation
First nine months of 2020
Novo Nordisk response to COVID-19 pandemic
Novo Nordisk status across the value chain
US GLP-1 prescription development during COVID-19 pandemic
• Manufacturing sites are operational
TRX count
(thousands)
TRX
NBRX (RHS)
NBRx count
(thousands)
•
Medicines available to patients worldwide
13 March, lockdown
implemented in most
Production
2,000
states
140
120
1,600
Continuation of all clinical trials already initiated
Trial recruitment still below pre-COVID-19 levels
Some new trials initiated
1,200
R&D
100
80
60
800
40
480
60
Gradual recovery of patient initiations in the
third quarter
400
20
20
Operations are running accordingly
.
Commercial
In many markets, sales representatives are
partially back in the field
0
0
Nov
Oct
Increased utilisation of digital tools
2018
2020
TRX: Total prescriptions; NBRx: New-to-brand prescriptions; RHS: Right-hand side axis
Source: IQVIA, each data point represents 4 weeks total, Oct 2020
Novo NordiskⓇView entire presentation